coloproctology

, Volume 36, Issue 3, pp 181–189 | Cite as

Reizdarmsyndrom – Epidemiologie und Pathophysiologie

Übersichten

Zusammenfassung

Das Reizdarmsyndrom (RDS) ist einer der häufigsten Gründe, warum Patienten den Arzt aufsuchen, und stellt hierdurch eine erhebliche sozioökonomische Belastung dar. Das RDS wurde aufgrund der geschichtlichen Entwicklung bisher symptomenbasiert definiert. Diese symptomenbasierte Definition durch Symptomencluster als Krankheit ist problematisch, da sich das hierdurch definierte Patientenkollektiv bezüglich des Krankheitsverlaufs nicht grundsätzlich von anderen Erkrankungen unterscheidet. Neuere Untersuchungen zeigen, dass das RDS mit verschiedenen strukturellen, molekularen, genetischen, immunologischen, nervalen und psychosozialen Veränderungen assoziiert ist. Die vielen heute diskutierten Pathomechanismen spiegeln zum einen den multifaktoriellen Charakter des RDS wider, sind zum anderen aber auch Hinweise auf pathophysiologisch unterschiedliche Erkrankungen. Es ist zu erwarten, dass in Zukunft die weitere Aufklärung pathophysiologisch relevanter Faktoren und insbesondere deren Korrelation mit den klinischen Symptomen die Diagnostik und Therapie des Reizdarmsyndroms verbessert. Es wird ein wesentliches Ziel sein, Biomarker zur Charakterisierung der zahlreichen RDS-Untergruppen zu finden, damit eine spezifische Therapieentscheidung möglich ist.

Schlüsselwörter

Reizdarmsyndrom Abdomineller Schmerz Blähungen Ausschlussdiagnose Biomarker 

Irritable bowel syndrome—epidemiology and pathophysiology

Abstract

Irritable bowel syndrome (IBS) is one of the most frequent reasons why patients seek medical care and therefore, causes a significant socioeconomic burden. Historically, IBS is primarily a symptom-based diagnosis but such a symptom clustering causes significant problems because it is not clear whether and how IBS differs from other diseases. Recent findings indicate that IBS is associated with well-defined structural, molecular, genetic, immunological, neural and psychosocial abnormalities. The numerous pathophysiological mechanisms of IBS reflect the multifactorial character of this disease and strongly suggest the existence of pathophysiologically different disease entities. It is expected that further insight into the pathophysiological mechanisms and the association with clinical symptoms will improve the diagnostics and therapy of IBS in the future. The major challenge will be the development of biomarkers to characterize IBS subgroups to enable therapeutic strategies which target specific pathomechanisms.

Keywords

Colonic diseases, functional Abdominal pain Flatulence Diagnosis by exclusion Biomarkers 

Literatur

  1. 1.
    Agreus L, Svardsudd K, Nyren O et al (1995) Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 109: 671–680PubMedCrossRefGoogle Scholar
  2. 2.
    Akbar A, Yiangou Y, Facer P et al (2008) Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 57: 923–929PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Camilleri M, McKinzie S, Busciglio I et al (2008) Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 6: 772–781PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Camilleri M (2012) Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 367: 1626–1635PubMedCrossRefGoogle Scholar
  5. 5.
    Cenac N, Andrews CN, Holzhausen M et al (2007) Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 117: 636–647PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Buhner S, Li Q, Berger T et al (2012) Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients. Neurogastroenterol Motil 24: 1134-e572PubMedCrossRefGoogle Scholar
  7. 7.
    Chaudhary NA, Truelove SC (1962) The irritable colon syndrome. A study of the clinical features, predisposing causes and prognosis in 130 cases. Q J Med 31: 307–322PubMedGoogle Scholar
  8. 8.
    Chang L, Adeyemo M, Karagiannides I et al (2012) Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 107: 262–272PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Cremon C, Gargano L, Morselli-Labate AM et al (2009) Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 104: 392–400PubMedCrossRefGoogle Scholar
  10. 10.
    Drossmann DA (2006) Rome III. The functional gastrointestinal disorders. Allen Press, Lawrence (Kansas)Google Scholar
  11. 11.
    Ellingson BM, Mayer E, Harris RJ et al (2013) Diffusion tensor imaging detects microstructural reorganization in the brain associated with chronic irritable bowel syndrome. Pain: epub ahead of print (pii: S0304-3959(13)00165-6. doi: 10.1016/j.pain.2013.04.010)Google Scholar
  12. 12.
    Frieling T, Schemann M, Pehl C (2011) Das Reizdarmsyndrom – eine Fehlbezeichnung? Z Gastroenterol 49: 577–578PubMedCrossRefGoogle Scholar
  13. 13.
    Frieling T, Meis K, Kolck UW et al (2011) Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z Gastroenterol 49: 191–194PubMedCrossRefGoogle Scholar
  14. 14.
    Gonlachanvit S, Mahayosnond A, Kullavanijaya P (2009) Effects of chili onpostprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceralnociception hypersensitivity. Neurogastroenterol Motil 21: 23–32PubMedCrossRefGoogle Scholar
  15. 15.
    Grover M, Herfarth H, Drossman DA (2009) The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol 7: 48–53PubMedCrossRefGoogle Scholar
  16. 16.
    Guilarte M, Santos J, Torres I de et al (2007) Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 56: 203–209PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Hughes PA, Harrington AM, Castro J et al (2012) Sensory neuro-immune interactions differ between Irritable Bowel Syndrome subtypes. Gut, doi: 10.1136/gutjnl-2011-301856Google Scholar
  18. 18.
    Klooker TK, Braak B, Koopman KE et al (2010) The mast cell stabiliserketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 59: 1213–1221PubMedCrossRefGoogle Scholar
  19. 19.
    Larsson MH, Simren M, Thomas EA et al (2007) Elevated motility-related transmucosal potential difference in the upper small intestine in their irritable bowel syndrome. Neurogastroenterol Motil 19: 812–820PubMedCrossRefGoogle Scholar
  20. 20.
    Layer P, Andresen V, Pehl C et al (2011) Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol 49: 237–293PubMedCrossRefGoogle Scholar
  21. 21.
    Mayer EA, Tillisch K (2011) The brain-gut axis in abdominal pain syndromes. Annu Rev Med 62: 381–396PubMedCrossRefGoogle Scholar
  22. 22.
    Piche T, Barbara G, Aubert P et al (2009) Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58: 196–201PubMedCrossRefGoogle Scholar
  23. 23.
    Spiller R, Lam C (2012) An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil 18: 258–268PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Steck N, Mueller K, Schemann M, Haller D (2012) Bacterialproteases in IBD and IBS. Gut 61: 1610–1618PubMedCrossRefGoogle Scholar
  25. 25.
    Swan C, Duroudier NP, Campbell E et al (2013) Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. Gut 62: 985–994PubMedCrossRefGoogle Scholar
  26. 26.
    Wanrooij SJM van, Wouters MM, Van Oudenhove L et al (2013) Sensitivity testing in irritable bowel syndrome with rectal capsaicin stimulations: role of TRPV1 upregulation and sensitization in visceral hypersensitivity. Gut (im Druck)Google Scholar
  27. 27.
    Whitehead WE, Holtkotter B, Enck P et al (1990) Tolerance for rectosigmoiddistention in irritable bowel syndrome. Gastroenterology 98: 1187–1192PubMedGoogle Scholar
  28. 28.
    Yale SH, Musana K, Kieke A et al (2008) Applying case definition criteria to irritable bowel syndrome. Clin Med Res 6: 9–16PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Zhou Q, Zhang B, Verne GN (2009) Intestinal membrane permeability and hypersensitivityin the irritable bowel syndrome. Pain 146: 41–46PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Medizinische Klinik II, Allgemeine Innere Medizin mit Gastroenterologie, Hepatologie, Neurogastroenterologie, Infektiologie, Hämatologie, Onkologie und PalliativmedizinHELIOS Klinikum KrefeldKrefeldDeutschland
  2. 2.Lehrstuhl HumanbiologieTechnische Universität MünchenFreisingDeutschland

Personalised recommendations